COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Data regarding symptoms in the lactating mother-infant dyad and their immune response to COVID-19 mRNA vaccination during lactation are needed to inform vaccination guidelines.
Methods
From a prospective cohort of 50 lactating individuals who received mRNA-based vaccines for COVID-19 (mRNA-1273 and BNT162b2), blood and milk samples were collected prior to first vaccination dose, immediately prior to 2nd dose, and 4-10 weeks after 2nd dose. Symptoms in mother and infant were assessed by detailed questionnaires. Anti-SARS-CoV-2 antibody levels in blood and milk were measured by Pylon 3D automated immunoassay and ELISA. In addition, vaccine-related PEGylated proteins in milk were measured by ELISA. Blood samples were collected from a subset of infants whose mothers received the vaccine during lactation (4-15 weeks after mothers’ 2nd dose).
Results
No severe maternal or infant adverse events were reported in this cohort. Two mothers and two infants were diagnosed with COVID-19 during the study period before achieving full immune response. PEGylated proteins were not found at significant levels in milk after vaccination. After vaccination, levels of anti-SARS-CoV-2 IgG and IgM significantly increased in maternal plasma and there was significant transfer of anti-SARS-CoV-2-Receptor Binding Domain (anti-RBD) IgA and IgG antibodies to milk. Milk IgA levels after the 2nd dose were negatively associated with infant age. Anti-SARS-CoV-2 IgG antibodies were not detected in the plasma of infants whose mothers were vaccinated during lactation.
Conclusions
COVID-19 mRNA vaccines generate robust immune responses in plasma and milk of lactating individuals without severe adverse events reported.
Article activity feed
-
-
-
-
-
SciScore for 10.1101/2021.03.09.21253241: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The University of California San Francisco (UCSF) institutional review board approved the study (20-32077, 20-30410).
Consent: Informed consent was obtained from all participants.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, maternal plasma was analyzed for anti-SARS-CoV-2 IgM and IgG antibodies, which were quantified through Pylon 3D automated immunoassay (considered positive if ≥ 50 relative fluorescence units (RFU)). anti-SARS-CoV-2 IgM and IgGsuggested: NoneHuman milk samples were assayed by ELISA for IgA antibodies specific to … SciScore for 10.1101/2021.03.09.21253241: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The University of California San Francisco (UCSF) institutional review board approved the study (20-32077, 20-30410).
Consent: Informed consent was obtained from all participants.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, maternal plasma was analyzed for anti-SARS-CoV-2 IgM and IgG antibodies, which were quantified through Pylon 3D automated immunoassay (considered positive if ≥ 50 relative fluorescence units (RFU)). anti-SARS-CoV-2 IgM and IgGsuggested: NoneHuman milk samples were assayed by ELISA for IgA antibodies specific to SARS-CoV-2 RBD protein. IgAsuggested: NoneSARS-CoV-2 RBD protein.suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-